Associação entre grau de incapacidade e presença de síndrome metabólica em adultos com esclerose múltipla

Victor Vincent Morais de Lima; Beatriz Melo de Carvalho; Rebeca Silvestre Chaves Silva; Nayranne Hívina Carvalho Tavares; Ana Bárbara Muniz Araújo; José Artur Costa D'Almeida; Maria Luísa Pereira de Melo

doi:10.52521/nutrivisa.v12i1.16255

Authors

Victor Vincent Morais de Lima Universidade Estadual do Ceará (UECE), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0001-8740-6385
Beatriz Melo de Carvalho Universidade Estadual do Ceará (UECE), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0002-3084-5616
Rebeca Silvestre Chaves Silva Universidade Estadual do Ceará (UECE), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0001-7655-6388
Nayranne Hívina Carvalho Tavares Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0002-3365-9552
Ana Bárbara Muniz Araújo Universidade Estadual do Ceará (UECE), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0001-6469-2139
José Artur Costa D'Almeida Universidade Federal do Ceará (UFC), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0002-6627-6515
Maria Luísa Pereira de Melo Universidade Estadual do Ceará (UECE), Fortaleza, Ceará, Brasil. https://orcid.org/0000-0002-3606-2217

DOI:

https://doi.org/10.52521/nutrivisa.v12i1.16255

Keywords:

body composition; disability evaluation; metabolic disease; demyelinating disease.

Abstract

Multiple sclerosis (MS) is a chronic, neurodegenerative, autoimmune disease that affects the central nervous system. Metabolic syndrome (MetS) is a set of metabolic disorders that increase the risk of cardiovascular diseases.

Multiple sclerosis (MS) is a chronic, neurodegenerative, autoimmune disease that affects the central nervous system and can cause severe functional sequelae. This study aimed to evaluate the presence of metabolic syndrome (MetS) in people living with MS and assess its association with disease progression. This cross-sectional study was conducted at the Interdisciplinary Center for Assistance, Research, and Education in Neuroimmunology (CIAPEN), located in Fortaleza, Ceará. The population consisted of adult patients aged ≥18 years diagnosed with MS according to the McDonald criteria. Data on sociodemographic, lifestyle (smoking, alcohol consumption, and physical activity), and clinical conditions (Expanded Disability Status Scale - EDSS, time since MS diagnosis) were collected. Nutritional assessment (body mass index - BMI, waist circumference - WC), hip circumference - HC, waist-to-hip ratio - WHR, body fat percentage - % BF) and biochemical tests (fasting blood glucose, total cholesterol - TC, low-density lipoprotein - LDL-c, high-density lipoprotein - HDL-c, triacylglycerols - TG) were performed. The diagnosis of MetS followed the criteria of the International Diabetes Federation. The results showed that the studied group had a mean age of 38.2 (10.34) years, disease duration of 6.76 years, and EDSS of 2.10 (1.92). Few patients had smoking habits (3; 4.4%) and alcohol consumption (25; 36.76%). Most participants were physically active (27; 39.70%), overweight/obese according to BMI (41; 60.29%) and % BF according to BIA (43; 63.23%), associated with central deposition of body fat, measured by WC (40; 58.82%). Regarding the biochemical profile, some patients had abnormal levels of fasting blood glucose (7; 10.29%), TC (26; 38.23%), LDL-c (22; 32.35%), TG (12; 17.64%), and HDL-c (24; 35.29%), with 17 (25%) patients of MetS. A positive association was also observed between EDSS and body composition (WC, % BF) and with TC, LDL-c, and TG values. Our results also observed a significant association between the EDSS score and the presence of MetS (p = 0.019). These results show the importance of considering strategies for preventing risk factors for MS in MS treatment.

References

ALBERTI, K. G.; ZIMMET, P.; SHAW, J.; IDF EPIDEMIOLOGY TASK FORCE CONSENSUS GROUP. The metabolic syndrome – a new worldwide definition. The Lancet, v. 366, n. 9491, p. 1059-1062, 2005. doi: https://doi.org/10.1016/S0140-6736(05)67402-8

ALBUQUERQUE, L. D. S.; DAMASCENO, N. R. T.; MAIA, F. N.; CARVALHO, B. M.; MAIA, C. S. C.; D'ALMEIDA, J. A. C.; MELO, M. L. P. Cardiovascular risk estimated in individuals with multiple sclerosis: A case-control study. Mult Scler Relat Disord, v. 54, p. 103133, 2021. doi: 10.1016/j.msard.2021.103133.

AYROMLOU, H.; HOSSEINI, S.; KHALILI, M.; AYROMLOU, S.; KHAMUDCHIYAN, S.; FARAJDOKHT, F.; HASSANNEZHAS, S., MOGHADAM, S. A. Insulin resistance is associated with cognitive dysfunction in multiple sclerosis patients: A cross-sectional study. J Neuroendocrinol, v. 35, n. 6, e13288, 2023. doi: 10.1111/jne.13288.

BRANDÃO, A. A.; RODRIGUES, C. I. S.; BORTOLOTTO, L. A.; ARMSTRONG, A. C.; MULINARI, R. A.; FEITOSA, A. D. M. et al. Diretriz Brasileira de Hipertensão Arterial – 2025. Arq Bras Cardiol, v. 122, n. 9, e20250624, 2025. doi: 10.36660/abc.20250624

BASSI, M. S.; IEZZI, E.; BUTTARI, F.; GILIO, L.; SIMONELLI, I.; CARBONE, F.; MICILLO, T.; DE ROSA, V.; SICA, F.; FURLAN, R.; FINARDI, A.; FANTOZZI, R.; STORTO M.; BELLANTONIO, P.; PIROLLO, P.; DI LEMME, S.; MUSELLA, A.; MANDOLESI, G.; CENTONZE, D.; MATARESE, G. Obesity worsens central inflammation and disability in multiple sclerosis. Mult Scler, v. 26, n. 10, p. 1237–1246, 2020. doi: 10.1177/1352458519853473.

BENEDETTI, T. R. B.; ANTUNES, P. C.; RODRIGUEZ-AÑEZ, C. R.; MAZO, G. Z.; PETROSKI, E. L. Reproducibility and validity of the International Physical Activity Questionnaire (IPAQ) in elderly men. Rev Bras Med Esporte, v. 13, n. 1, 2007. doi: 10.1590/S1517-86922007000100004.

BRASIL. Ministério da Saúde. Conselho Nacional de Saúde. Resolução CNS no 466/2012 – Diretrizes e Normas Regulamentadoras de Pesquisas Envolvendo Seres Humanos. Diário Oficial da União. Brasília, DF, 2012.

BRIGGS, F. B. S.; HILL, E.; ABBOUD, H. The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States. Eur J Neurol, v. 28, n. 2, p. 558–566, 2021. doi: 10.1111/ene.14557

CARVALHO, B. M.; SILVA, R. S. C.; LIMA, V. V. M.; ALMONDES, K.G. S.; RODRIGUES, F. N. S.; D’ALMEIDA, J. A. C.; MELO, M. L. P. Excess weight increases the risk of sarcopenia in patients with multiple sclerosis. Mult Scler Relat Disord, v.79, p.105049, 2023. doi: 10.1016/j.msard.2023.105049.

CASSIANO, D.P.; SANTOS, A.H.R.; ESTEVES, D.C.; ARAÚJO, G.N.; CAVALCANTI, I. C.; ROSSI, M.; SENA, M.S.; SOUZA, R.O. Estudo epidemiológico sobre internações por esclerose múltipla no Brasil comparando sexo, faixa etária e região entre janeiro de 2008 a junho de 2019. Braz J Health Rev, v.3, n.6, p.19850–19861, 2020. doi:10.34119/bjhrv3n6-359.

CASTRO-BARQUERO, S.; CASAS, R.; RIMM, E. B.; TRESSERRA-RIMBAU, A.; ROMAGUERA, D.; MARTÍNEZ, J. A.; SALAS-SALVADÓ, J.; MARTÍNEZ-GONZÁLEZ, M. A.; VIDAL, J.; RUIZ-CANELA, M.; KONIECZNA, J.; SACANELLA, E.; GARCÍA-

GAVILÁN, J. F.; FITÓ, M.; GARCÍA-ARELLANO, A.; ESTRUCH, R. Loss of visceral fat is associated with a reduction in inflammatory status in patients with metabolic syndrome. Mol Nutr Food Res, v. 67, n. 4, e2200264, 2023. doi:10.1002/MNFR.202200264.

CONWAY, D. S.; TOLJAN, K.; HARRIS, K. A.; GALIOTO, R.; BRIGGS, F. B.; HERSH, C. M. Body mass index trends over four years in persons with multiple sclerosis. Mult Scler Relat Disord, v. 93, p. 106218, 2024. doi: 10.1016/j.msard.2024.106218.

DAGAN, A.; GRINGOUZ, I.; KLIERS, I.; SEGAL, G. Disability progression in multiple sclerosis is affected by the emergence of comorbid arterial hypertension. J Clin Neurol. v. 12, n. 3, 345–350, 2016. doi: 10.3988/jcn.2016.12.3.345.

DOBSON, R.; GIOVANNONI, G. Multiple sclerosis - a review. Eur J Neurol, v. 26, n. 1, 27, 2019. doi: 10.1111/ene.13819.

DOLCETTI, E.; BRUNO, A.; GUADALUPI, L.; RIZZO, F. R.; MUSELLA, A.; GENTILE, A.; DE VITO, F.; CAIOLI, S.; BULLITTA, S.; FRESEGNA, D.; VANNI, V.; BALLETTA, S.; SANNA, K.; BUTTARI, F.; BASSI, M. S.; CENTONZE, D.; MANDOLESI, G. Emerging role of extracellular vesicles in the pathophysiology of multiple sclerosis. Int J Mol Sci. v. 21, n. 19, p. 7336, 2020. doi: 10.3390/ijms21197336.

DOSSI, D. E.; CHAVES, H.; HECK, E. S.; RODRIGUEZ, S. M.; VENTRICE, F.; BAKSHI, R.; QUINTANA, F. J.; CORREALE, J.; FAREZ, M. F. Effects of systolic blood pressure on brain integrity in multiple sclerosis. Front Neurol, v. 9, p. 487, 2018. doi: 10.3389/fneur.2018.00487.

DREHMER, E.; PLATERO, J. L.; CARRERA-JULIÁ, S.; MORENO, M. L.; TVARIJONAVICIUTE, A.; NAVARRO, M. Á.; LÓPEZ-RODRÍGUEZ, M. M.; ORTÍ, J. E. R. The Relation between eating habits and abdominal fat, anthropometry, PON1 and IL-6 levels in patients with multiple sclerosis. Nutrients, v. 12, n. 3, p. 744, 2020. doi: 10.3390/nu12030744.

FAHMI, R. M.; EL EBEARY, M. E. S.; ABD ALRASHEED, E. M.; ELKHATIB, T. H. M. Metabolic syndrome components and disease disability in egyptian multiple sclerosis patients. Mult Scler Related Disord, v. 44, p. 102336, 2020. doi: 10.1016/j.msard.2020.102336.

FITZGERALD, K. C.; SALTER, A.; TYRY, T.; FOX, R. J.; CUTTER, G.; MARRIE, R. A. Medidas de obesidade geral e abdominal e gravidade da incapacidade em uma grande população de pessoas com esclerose múltipla. Mult Scler, v.26, n.8, p.976- 986, 2020. doi: 10.1177/1352458519845836.

GAUTHIER, H.; ZEDET, M.; WAHAB, A.; BALDÉ, S.; BAPST, B.; LAFONT, C.; CRÉANGE, A. Metabolic syndrome and the phenotype of multiple sclerosis. Rev Neurol, v. 180, n. 7, p. 673–681, 2024. doi: 10.1016/j.neurol.2024.03.009.

GIANNOPAPAS, V.; STEFANOU, M. I.; SMYRNI, V.; KITSOS, D. K.; KOSMIDOU, M.; STASI, S.; GIANNOPOULOS, S. Waist circumference and body mass index as predictors of disability progression in multiple sclerosis: a systematic review and meta-analysis. J Clin Med, v. 13, n. 6, p.1739, 2024. doi: 10.3390/jcm13061739.

GRANZIERA, C; DERFUSS, T.; KAPPOS, L. Time to Change the Current Clinical Classification of Multiple Sclerosis? JAMA Neurology, v. 80, n. 2, p. 128-130, 2022. doi:10.1001/jamaneurol.2022.4156

HAKI, M.; AL-BIATI, H. A.; AL-TAMEEMI, Z. S.; ALI, I. S.; AL- HUSSAINY, H. A. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine, v. 103, n. 8, e37297, 2024. doi: 10.1097/MD.0000000000037297.

INTERNATIONAL DIABETES FEDERATION. ALBERTI, G.; ZIMMET, P.; SHAW, J.; SCOTT, M. G. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006.

KURTZKE, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, v. 11, n. 33, p. 1444-1452, 1983. doi: 10.1212/wnl.33.11.1444.

KYLE, U. G.; BOSAEUS, I.; DE LORENZO, A. D.; DEURENBERG, P.; ELIA, M.; GÓMEZ, J. M.; HEITMANN, B. L.; KENT-SMITH, L.; MELCHIOR, J. C.; PIRLICH, M.; SCHARFETTER, H.; SCHOLS, A. M. W. J.; PICHARD, C.; ESPEN. Bioelectrical impedance analysis – part II: utilization in clinical practice. Clin Nutr, v. 23, n. 6, p. 1430-1453, 2004. doi: 10.1016/j.clnu.2004.09.012

LIPSCHITZ, D. A. Screening for nutritional status in the elderly. Primary Care, v. 21, n. 1, p. 55-67, 1994.

LIVNE-MARGOLIN, M.; LATZER, I. T.; PINHAS-HAMIEL, O.; HARARI, G.; ACHIRON, A. Bodyweight measures and lifestyle habits in individuals with multiple sclerosis and moderate to severe disability. J Clin Med, v. 10, n. 10, p. 2083, 2021. doi: 10.3390/jcm10102083.

LOHMAN, T. G.; HOUTKOOPER, L.; GOING, S. B. Body fat measurements go high-tech: not all are created equal. Med Sci Sports Exerc, v. 1, p. 30-35, 1997.

LUTFULLIN, I.; EVESLAGE, M.; BITTNER, S.; ANTONY, G.; FLASKAMP, M.; LUESSI, F.; SALMEN, A.; GISEVIUS, B.; KLOTZ, L.; KORSUKEWITZ, C.; BERTHELE, A.; GROPPA, S.; THEN, F. B.; WILDEMANN, B.; BAYAS, A.; TUMANI, H.; MEUTH, S. G.; TREBST, C.; ZETTL, U. K.; PAUL, F.; HEESEN, C.; KUEMPFEL, T.; GOLD, R.; HEMMER, B.; ZIPP, F.; WIENDL, H.; LUNEMANN, J. D. German Competence Network Multiple Sclerosis (KKNMS) Association of obesity with disease outcome in multiple sclerosis. J Neurol Neurosurg Psychiatry, v. 94, n. 1, p. 57–61, 2023. doi: 10.1136/jnnp-2022-329685.

MARCK, C. H.; NEATE, S. L.; TAYLOR, K. L.; WEILAND, T. J.; JELINEK, G. A. Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PloS one. v. 11, n. 2, e0148573, 2016. doi: 10.1371/journal.pone.0148573.

MATUSIK, E.; DURMALA, J.; KSCIUK, B.; MATUSIK, P. Body composition in multiple sclerosis patients and its relationship to the disability level, disease duration and glucocorticoid therapy. Nutrients, v. 14, n. 20, p. 4249, 2022. doi: 10.3390/nu14204249.

MILLER, M.; STONE, N. J.; BALLANTYNE, C.; BITTNER, V.; CRIQUI, M. H.; GINSBERG, H. N.; GOLDBERG, A. C.; HOWARD, W. J.; JACOBSON, M. S.; KRIS-ETHERTON, P. M.; LENNIE, T. A.; LEVI, M.; MAZZONE, T.; PENNATHUR, S. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, v. 123, n. 20, p. 2292–2333, 2011. doi: 10.1161/CIR.0b013e3182160726.

MORAIS, M. P. S.; CARVALHO, B. M. de; PEREIRA, R. S.; AVELINO, L. L. de S.; D’ALMEIDA, J. A. C.; MELO, M. L. P. de. Esclerose Múltipla: associação do estado nutricional e qualidade de vida. Nutrivisa, v. 12, n. 1, p. e14552, 2025. doi: 10.52521/nutrivisa.v12i1.14552.

OLEK, M. J. Multiple Sclerosis. Ann Intern Med, v.174, n.6, p.81-89, 2021. doi: 10.7326/AITC202106150.

OLIVEIRA, S. R.; SIMÃO, A. N.; KALLAUR, A. P.; DE ALMEIDA, E. R.; MORIMOTO, H. K.; LOPES, J.; DICHI, I.; KAIMEN-MACIEL, D. R.; REICHE, E. M. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition, v. 30, n. 3, p. 268–273, 2014. doi: 10.1016/j.nut.2013.08.001.

OLIVEIRA, A. K. P.; FERNANDES, K. N. P.; SILVA, C. E. V. Explorando a utilização da ultrassonografia modo A portátil para a avaliação da composição corporal: Uma revisão narrativa. Res, Soc Dev, v. 13, n1, e54613144888, 2024. doi: 10.52058/2525-5031-rsd-v13i1-5461314488.

PALLADINO, R.; MARRIE, R. A.; MAJEED, A.; CHATAWAY, J. Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England. JAMA Neurol, v. 77, p. 820–828, 2020. doi: 10.1001/jamaneurol.2020.0664.

POLMAN C. H.; REINGOLD S. C; BANWELL B.; CLANET M.; COHEN J. A.; FILIPPI M.; FUJIHARA K.; HAVRDOVA E.; HUTCHINSON M.; KAPPOS L.; LUBLIN F. D.; MONTALBAN X.; O'CONNOR P.; SANDBERG-WOLLHEIM M.; TROMPSON A. J.; WAUBANT E.; WEINSHENKER B.; WOLINSKY J. S. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol, v. 69, p. 292, 2011. doi: 10.1016/S1474-4422(17):30470-2.

PORTACCIO, E.; MAGYARI, M.; HAVRDOVA, E. K.; RUET, A.; BROCHET, B.; SCALFARI, A.; DI FILIPPO, M.; TUR, C.; MONTALBAN, X.; AMATO, M. P. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur, v. 44, p. 100977, 2024. doi: 10.1016/j.lanepe.2024.100977.

RODACKI, M.; COBAS, R. A.; ZAJDENVERG, L.; SILVA JÚNIOR, W. S.; GIACAGLIA, L.; CALLIARI, L. C.; NORONHA, R. M.; VALERIO, C.; CUSTÓDIO, J.; SCHARF, M.; BARCELLOS, C. R. G.; ALMEIDA-PITITTO B.; NEGRATO C. A.; GABBAY M.; BERTOLUCI M. Diagnóstico de diabetes mellitus. Diretriz Oficial da Sociedade Brasileira de Diabetes, 2024. doi: 10.29327/5412848.2024-1.

ROSENBERG, J.; NATARAJAN, J.; CARPENTER, D. J.; PELUSO, C.; HILTON, C.; CHAMP, C. E. Agreement Between Bioelectrical Impedance Analysis and Ultrasound for Measuring Body Composition in Women with Breast Cancer. Diagnostics, v. 15, n. 12, p. 1545, 2025. doi.org/10.3390/diagnostics15121545

SHI, M.; LIU, Y.; GONG, Q.; XU, X. Multiple sclerosis: an overview of epidemiology, risk factors, and serological biomarkers. Acta Neurol Scand, v. 2024, n. 1, p. 7372789, 2024. doi:10.1155/2024/7372789.

SOCIEDADE BRASILEIRA DE CARDIOLOGIA. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol, v. 109, n. 1, 2017. doi: 10.5935/abc.20170121.

SOCIEDADE BRASILEIRA DE CARDIOLOGIA. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol. v. 116, n. 3, p. 516, 2021. doi: 10.36660/abc.20201238.

SEPIDARKISH, M.; KALANTARI, N.; GORGANI-FIROUZJAEE, T.; ROSTAMI-MANSOOR, S.; SHIRAFKAN, H. Association between insulin resistance and multiple sclerosis: a systematic review and meta-analysis. Metab Brain Dis, v. 39, n. 5, p. 1015, 2024. doi: 10.1007/s11011-024-01347-2.

SILVA, A. S.; GUIMARÃES, J.; SOUSA, C.; MENDONÇA, L.; SOARES-DOS-REIS, R.; MENDONÇA, T.; ABREU, P.; SEQUEIRA, L.; SÁ, M. J. Metabolic syndrome parameters and multiple sclerosis disease outcomes: a Portuguese cross-sectional study. Mult Scler Relat Disord, v. 69, p. 104370, 2023. doi: 10.1016/j.msard.2022.104370.

SOLIMAN, R. H.; FARHAN, H. M.; HEGAZY, M. ORABY, M. I.; KAMEL, S. H.; HASSAN, A. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis. Egypt J Neurol Psychiat Neurosurg, v. 56, n. 18, 2020. doi:10.1186/s41983-020-0155-y.

STOILOUDIS, P.; KESIDOU, E.; BAKIRTZIS, C.; SINTILA, S. A.; KONSTANTINIDOU, N.; BOZIKI, M.; GRIGORIADIS, N. The role of diet and interventions on multiple sclerosis: a review. Nutrients, v. 14, n. 6, p. 1150, 2022. doi: 10.3390/nu14061150.

SUKRIYA, S.; KHURANA, D.; BHADAD, S.; SINGH, P.; RAY, S. Prevalence of insulin resistance and dyslipidemia in multiple sclerosis and its correlation with disease activity. J Neurol Sci, v. 429, p.118128, 2021. doi:10.1016/j.jns.2021.118128.

TETTEY, P.; SIMPSON, S.; JR, B. T.; BLIZZARD, L.; PONSONBY, A. L.; DWYER, T.; KOSTNER, K.; VAN DER MEI, I. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler, v. 20, p. 1737–1744, 2014. doi: 10.1177/1352458514533162.

TANOH, I. C.; MAILLART, E.; LABAUGE, P.; COHEN, M.; MAAROUF, A.; VUKUSIC, S.; DONZÉ, C.; GALLIEN, P.; DE SÈZE, J.; BOURRE, B.; MOREAU, T.; LOUAPRE, C.; VALLÉE, M.; BIEUVELET, S.; KLAEYLÉ, L.; ARGOUD, A. L.; ZINAÏ, S.; TOURBAH, A. MSCopilot: New smartphone-based digital biomarkers correlate with expanded disability status scale scores in people with multiple sclerosis. Mult Scler Relat Disord, n. 55, 103164, 2021. doi:10.1016/j.msard.2021.103164

VAN HIJFTE, L.; LORET, G.; BACHMANN, H.; REYNDERS, T.; BREULS, M.; DESCHEPPER, E.; KUHLE, J.; WILLEKENS, B.; LAUREYS, G. Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study. Mult Scler Relat Disord, v. 65, p. 104016, 2022. doi: 10.1016/j.msard.2022.104016.

VASCONCELOS, F. A. G. Avaliação nutricional de coletividades. 4. ed. rev. e ampl. Florianópolis: Ed. UFSC, 2008.

VESA, C. M.; ZAHA, D. C.; BUNGAU, S. G. Molecular Mechanisms of Metabolic Syndrome. Int J Mol Sci, v. 25, n. 10, p. 5452, 2024. doi: 10.3390/ijms25105452.

VESPASIANO, B. S.; DIAS, R. C. D. A. A utilização do Questionário Internacional de Atividade Física (Ipaq) como ferramenta diagnóstica do nível de aptidão física: uma revisão no Brasil. S Rev, v. 12, n. 32, p. 49-54, 2012. doi: 10.15600/2238-1244/sr.v12n32p49-54.

WENS, I.; DALGAS, U.; DECKX, N.; COOLS, N.; EIJNDE, B. O. Does multiple sclerosis affect glucose tolerance? Mult Scler, v. 20, n. 9, p. 1273–1276, 2014. doi: 10.1177/1352458513515957.

WORLD HEALTH ORGANIZATION. Obesity Preventing and Managing the Global Epidemic. World Health Organization, p. 276. 1998.

WU, J.; ALFREDSSON, L.; OLSSON, T.; HILLERT, J. A.; HEDSTROM, A. K. Obesity affects disease activity and progression, cognitive functioning, and quality of life in people with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm, v. 12, n. 1, e200334, 2025. doi: 10.1212/NXI.0000000000200334.